Table 1 (abstract A24). Characteristics of Children with Juvenile Idiopathic Arthritis and Uveitis
N (%), unless indicated | Overall | JIAa alone (n = 22) | JIA-Ub (n = 22) | Other Uc (n = 18) |
|---|---|---|---|---|
Characteristics | Â | Â | Â | Â |
Demographics | Â | Â | Â | Â |
Age, Mean (SD)d | 13.0 (3.3) | 12.9 (2.8) | 12.6 (3.4) | 13.5 (3.9) |
Gender, Male | 14 (22.6) | 2 (9.1) | 4 (18.2) | 8 (44.4) |
Race | ||||
 White | 53 (85.5) | 21 (95.5) | 20 (90.9) | 12 (66.7) |
 African American | 5 (8.1) | 1 (4.5) | 1 (4.5) | 3 (16.7) |
 American Indian/Alaskan Native | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 Asian | 1 (1.6) | 0 (0.0) | 1 (4.5) | 0 (0.0) |
 Multi-racial | 1 (1.6) | 0 (0.0) | 0 (0.0) | 1 (5.6) |
 Unknown/Declined | 2 (3.2) | 0 (0.0) | 0 (0.0) | 2 (11.1) |
Ethnicity, Hispanic | 1 (1.6) | 0 (0.0) | 1 (4.7) | 0 (0.0) |
JIA Characteristics | ||||
 Age at Diagnosis, Mean (SD) | 6.3 (4.6) | 7.7 (4.3) | 4.9 (4.2) |  |
 Duration of Disease, years, Mean (SD) | 6.5 (4.3) | 5.2 (3.7) | 7.7 (4.7) |  |
 JIA Subtype | ||||
  Oligoarticular Persistent | 14 (31.8) | 10 (45.5) | 4 (18.2) |  |
  Oligoarticular Extended | 9 (20.5) | 3 (13.6) | 6 (27.3) |  |
  Polyarticular RF(-) | 17 (38.6) | 9 (40.9) | 8 (36.4) |  |
Uveitis Characteristics | ||||
 Age at Diagnosis, Mean (SD) | 8.4 (4.5) |  | 6.1 (4.0) | 11.4 (3.0) |
 Duration of Disease, years, Mean (SD) | 4.8 (4.3) |  | 6.4 (4.7) | 2.8 (2.8) |
 Bilateral Disease |  |  | 17 (77.2) | 12 (66.7) |
 Anterior Chamber Cells >0.5+ |  |  | 1 (4.6) | 2 (11.1) |
 Visual Acuity 20/50 or worse |  |  | 0 (0.0) | 0 (0.0) |
 Location |  |  |  |  |
  Anterior |  |  | 22 (100.0) | 13 (72.2) |
  Intermediate |  |  | 1 (4.5) | 3 (1.7) |
  Posterior |  |  | 0 (0.0) | 1 (5.5) |
  Panuveitis |  |  | 0 (0.0) | 2 (11.1) |
Ocular Complications, ever | ||||
 Glaucoma or Glaucoma Suspect | 21 (33.9) |  | 11 (50.0) | 10 (55.6) |
 Cataracts | 16 (25.8) |  | 10 (45.5) | 6 (33.3) |
 Synechiae | 11 (17.7) |  | 8 (36.4) | 3 (16.7) |
 Band Keratopathy | 4 (6.5) |  | 1 (4.5) | 3 (16.7) |
 Amblyopia | 3 (4.8) |  | 2 (9.1) | 1 (5.6) |
 Cystoid Macular Edema | 1 (1.6) |  | 1 (4.5) | 0 (0.0) |
 Othere | 1 (1.6) |  | 0 (0.0) | 1 (5.6) |
Treatment, at time of visit | ||||
 Steroid drops | 24 (38.7) |  | 11 (50.0) | 13 (72.2) |
 Dilating drops | 2 (3.2) |  | 2 (9.1) | 0 (0.0) |
 IOP-lowering dropsf | 5 (8.1) |  | 1 (4.5) | 4 (22.2) |
 Methotrexate oral | 12 (19.4) | 5 (22.7) | 5 (22.7) | 2 (11.1) |
 Methotrexate SQ | 10 (16.1) | 3 (13.6) | 4 (18.2) | 3 (16.7) |
 Mycophenolate | 2 (3.2) | 0 (0.0) | 1 (4.5) | 1 (5.6) |
 Etanercept | 4 (6.5) | 4 (18.2) | 0 (0.0) | 0 (0.0) |
 Infliximab | 12 (19.4) | 1 (4.5) | 6 (27.3) | 5 (27.8) |
 Adalimumab | 9 (14.5) | 2 (9.1) | 6 (27.3) | 1 (5.6) |
 Abatacept | 1 (1.6) | 0 (0.0) | 1 (4.5) | 0 (0.0) |
 Tocilizumab | 7 (11.3) | 3 (13.6) | 4 (18.2) | 0 (0.0) |